Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership

Wednesday, August 22, 2007 General News
Email Print This Page Comment
Font : A-A+

MENLO PARK, Calif. and HUNTSVILLE, Ala., Aug. 22 DNA2.0Inc. (www.DNA20.com), the largest US provider of synthetic genes, and OperonBiotechnologies (www.operon.com), a leader in DNA oligonucleotide synthesis,announce the formation of a partnership to utilize their synergistictechnologies and product lines.

By combining Operon's oligonucleotide production platform with DNA2.0'sgene synthesis process, the companies expect to further increase DNA2.0'smarket leading speed of synthesis, while providing Operon access to thefastest growing application area for oligonucleotides today. The partnershipwill allow each company to remain focused on their respective core businesses,while the customer benefits from the expertise of both partners.

Under the partnership, Operon will co-market DNA2.0's gene synthesisservices. 'DNA2.0 provides products and a level of customer service that isunparalleled in the gene synthesis industry, we wholeheartedly recommend themto our customers for their synthetic genes.' said Patrick A. Weiss, CEO ofOperon. 'We at Operon are proud to be the primary source of the oligos that gointo DNA2.0 synthetic genes.'

'Construction of synthetic genes requires oligos of only the highestquality' said Jeremy Minshull, President of DNA2.0. 'Operon's fully automatedoligo synthesis process meets our exacting quality requirements, and theirspeed and responsiveness makes Operon an outstanding partner for DNA2.0 in thegene synthesis marketplace.'

About DNA2.0 Inc.

DNA2.0 is the largest US provider of synthetic genes, serving customersglobally in the pharmaceutical and biotechnology industries as well as inacademia. The company is also pioneering the application of machine learningto commercial protein engineering through their ProteinGPS(TM) platform. Formore information please visit www.DNA20.com.

About Operon Biotechnologies

Operon Biotechnologies is a global market leader in high-throughputsynthesis, serving scientists in academic research, biotechnology, andpharmaceutical development. Through our production facilities in the US,Germany, and Japan, as well as distributors worldwide, Operon provides a widerange of quality DNA oligonucleotides, Array Ready Oligo Sets (AROS(TM)) andpre-printed microarrays (OpArray(TM)). Since its inception in 1986, Operon hasbeen driven by incomparable customer service and reliable delivery of qualityproducts. Operon employs advanced synthesis technologies and consistentlypursues unique innovations to maintain the highest level of excellence in bothproducts and support. For more information please visit www.operon.com.

SOURCE Operon Biotechnologies


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook